{
    "clinical_study": {
        "@rank": "78935", 
        "acronym": "EnligHTN III", 
        "arm_group": {
            "arm_group_label": "Renal Artery Ablation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this First-in-Human Clinical investigation is to evaluate the safety and\n      performance of the St. Jude Medical EnligHTN\u2122 Generation 2 Renal Denervation System for the\n      treatment of patients with drug-resistant uncontrolled hypertension."
        }, 
        "brief_title": "International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension", 
            "Renal Denervation"
        ], 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is \u2265 18 and \u2264 80 years of age at time of consent\n\n          -  Subject must be able and willing to provide written informed consent\n\n          -  Subject must be able and willing to comply with the required follow-up schedule\n\n          -  Subject has office Systolic Blood Pressure \u2265 160 mmHg at confirmatory visit\n\n          -  Subject has a daytime mean Systolic Ambulatory Blood Pressure > 135 mmHg during the\n             two week screening period\n\n          -  Subject has an office Systolic Blood Pressure that remains \u2265160 mmHg despite the\n             stable use of \u22653 antihypertensive medications concurrently at maximally tolerated\n             doses, of which one is a diuretic or subject was previously on diuretic but\n             documented to be diuretic intolerant, for a minimum of 14 days prior to the procedure\n             and with an expectation to maintain for a minimum of 180 days post procedure.\n\n        Exclusion Criteria:\n\n          -  Subject has significant renovascular abnormalities such as renal artery stenosis >\n             30% in either renal artery\n\n          -  Subject has undergone prior renal angioplasty, renal denervation, indwelling renal\n             stents, and/or abdominal aortic stent grafts\n\n          -  Subject has hemodynamically significant valvular heart disease as determined by the\n             Study Investigator\n\n          -  Subject has a life expectancy less than 12 months, as determined by a Study\n             Investigator\n\n          -  Subject is participating in another clinical study which has the potential to impact\n             their hypertension management (pharmaceutical/device/homeopathic)\n\n          -  Subject is pregnant, nursing, or of childbearing potential and is not using adequate\n             contraceptive methods\n\n          -  Subject has active systemic infection\n\n          -  Subject has renal arteries with diameter(s) < 4 mm in diameter or <20 mm in length\n\n          -  Subject has an estimated Glomerular Filtrate Rate (eGFR) <45 mL/min per 1.73 m2 using\n             the Modified Diet in Renal Disease (MDRD) formula\n\n          -  Subject has Diabetes Mellitus Type I\n\n          -  Subject has multiple main renal arteries in either kidney\n\n          -  Subject has an identified secondary cause of hypertension (for example, including,\n             but not limited to, Polycystic kidney disease, Cushing's syndrome, Aldosteronism)\n\n          -  Subject has evidence of significant abdominal aortic aneurysm (defined as maximum\n             diameter of >4 cm)\n\n          -  Subject has had a myocardial infarction, unstable angina pectoris or cerebrovascular\n             accident less than 180 days prior to enrollment\n\n          -  Subject is expected to have cardiovascular intervention within the next 180 days\n\n          -  Subject has a condition which would interfere with the accurate interpretation of the\n             study objectives including but not limited to a large arm diameter that is unable to\n             accommodate the blood pressure cuff or arrhythmia that interferes with automatic\n             pulse sensing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01836146", 
            "org_study_id": "1202"
        }, 
        "intervention": {
            "arm_group_label": "Renal Artery Ablation", 
            "intervention_name": "EnligHTN\u2122 Renal Artery Ablation Catheter", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 29, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia"
                    }, 
                    "name": "St Andrews Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fizroy", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "St. Vincent's Hospital Melbourne"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Royal Melbourne Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "Monash Heart/Southern Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "1023"
                    }, 
                    "name": "Auckland City Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dunedin", 
                        "country": "New Zealand", 
                        "zip": "9016"
                    }, 
                    "name": "Dunedin Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "1", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Human Research Ethics Committee", 
                "New Zealand: Health and Disability Ethics Committees"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To characterize the rate of serious procedural and device related adverse events from date of procedure through 6 months post procedure, as adjudicated by the Clinical Events Committee (CEC).", 
                "measure": "Safety Objective", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To characterize the reduction of office Systolic Blood Pressure at 6 months post procedure as compared to baseline.", 
                "measure": "Performance objective", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01836146"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Characterization of the change in Ambulatory Blood Pressure parameters over time as compared to baseline", 
                "measure": "Change in Ambulatory Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "1 month, 3 month, 6 month, 12 month, 18 month, 2 years"
            }, 
            {
                "description": "Characterization of renovascular safety as measured by new renal artery stenosis or aneurysm at the site of ablation over time as compared to baseline", 
                "measure": "New renal artery stenosis or aneurysm at the site of ablation", 
                "safety_issue": "No", 
                "time_frame": "1 month, 3 month, 6 month, 12 month, 18 month, 2 years"
            }, 
            {
                "description": "Characterization of renal function change over time as compared to baseline as measured by changes in: eGFR, serum creatinine and cystatin C", 
                "measure": "Renal Function Change", 
                "safety_issue": "No", 
                "time_frame": "1 month, 3 month, 6 month, 12 month, 18 month, 2 years"
            }
        ], 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}